Protara Stock Plummets on Bladder Cancer Trial Results

Protara Therapeutics Stock Declines After Trial Data Release

Protara Therapeutics Inc. (NASDAQ:TARA) experienced a significant 19% drop in its stock price during after-hours trading. The decline followed the company's announcement of updated interim results from its Phase 2 ADVANCED-2 clinical trial for TARA-002.

Overview of Trial Results

The trial evaluates TARA-002, an investigational therapy for high-risk Non-Muscle Invasive Bladder Cancer. In the BCG-Unresponsive patient group, the complete response rate was 68.2% at six months but decreased to 33.3% at the 12-month mark. For the BCG-Naïve group, the complete response rate was 66.7% at six months and 57.9% at 12 months. The therapy was generally well-tolerated with no serious treatment-related adverse events reported.

Impact on the Market

The sharp 19% fall in share price reflects negative investor sentiment regarding the trial data. The drop in efficacy over time, particularly in the BCG-Unresponsive cohort, likely raised concerns about the long-term durability of the treatment's response, overshadowing the positive safety profile. The market's reaction highlights sensitivity to long-term clinical outcomes for developmental-stage biopharmaceutical companies.

Summary and Next Steps

Protara Therapeutics plans to complete enrollment for its registrational cohort in the second half of 2026 and initiate a new trial for BCG-Naïve patients. The company will present the full results at the American Society of Clinical Oncology Genitourinary Cancers Symposium, providing further details to the medical and investment communities.

FAQ

Q: Why did Protara Therapeutics' stock fall sharply?
A: The stock fell 19% after the company released Phase 2 trial data for its bladder cancer therapy, TARA-002. The results suggested a decline in treatment effectiveness over 12 months, which concerned investors.

Q: What is TARA-002?
A: TARA-002 is an investigational cell-based therapy being developed for patients with high-risk Non-Muscle Invasive Bladder Cancer.

Source: Investing.com